INSM accumulation or distribution?I assume distribution. Hard to value a 1-approved-drug bio company with a not-yet-commercialized cure for a self-described 'rare condition' at 13B .
Also usually when things go up a lot they come down a bit first?
INSM trade ideas
INSM - June 24 Qullamaggie Breakout and Episodic Pivot15 June
Price surfing the 10SMA and making lower highs
There are two large momentum candles bringing price above the consolidation.
It was also one of the rare stocks that was green while the broader market was red
Risk
I know the reason for the new pricing but I am unable to determine if it is so impactful that it justifies a 122% spike. But technicals seem to align for so i am entering
Insmed Catapults 113% on Positive ASPEN Study ResultsInsmed ( NASDAQ:INSM ), a biotech company, has successfully developed a lung disease drug, brensocatib, which has been shown to significantly reduce the frequency of respiratory symptoms such as chronic cough in a late-stage study. The drug, which is expected to be launched in mid-2025, is expected to be approved by the FDA in the fourth quarter of this year. The company also plans to launch the drug in Europe and Japan in the first half of 2026.
Bronchiectasis is a chronic lung disease that affects 350,000 to 500,000 adults in the United States and has no approved treatments currently. The results validate Insmed's theory that blocking an enzyme called DPP1 can help treat some inflammatory diseases. The market potential for brensocatib is "very attractive," with the potential to expand several-fold with a simple CT scan, potentially identifying more NCFB patients who are currently diagnosed with COPD (chronic obstructive pulmonary disease).
Insmed ( NASDAQ:INSM ) tested two doses of brensocatib, with the low dose leading to a 21.1% reduction in the number of lung exacerbations a patient would be expected to experience in a year, while the high dose led to a 19.4% reduction in the annualized rate of pulmonary exacerbations. The results were encouraging, but questions remain about whether patients received Arcturus' drug on top of Vertex Pharmaceuticals' Trikafta, a standard treatment for cystic fibrosis.
Insmed ( NASDAQ:INSM ) stock has skyrocketed 112.9% to 46.84 in morning trades on the stock market. The low dose led to a 21.1% reduction in the number of lung exacerbations a patient would be expected to experience in a year, while the high dose resulted in a 19.4% reduction in the annualized rate of pulmonary exacerbations.
In related news, Arcturus Therapeutics (ARCT) stock soared 23.1% to 37.42 on a positive update for its cystic fibrosis treatment. Patients with cystic fibrosis have mutations in their CFTR gene, and Arcturus uses an inhaled drug to deliver messenger RNA to patients' lungs. Four patients received two doses of Arcturus' drug over eight days, and on average, they had a 4% improvement in how much air they could expel for one second, a key test of lung function in cystic fibrosis.
Insmed stock ( NASDAQ:INSM ) has outperformed lately and has bounded off its 50-day Moving Average (MA) on the news. The stock is currently overbought trading with a Relative Strength Index (RSI) of 83.47.
INSM Cash Secured putThis looks intriguing as premium for CSPs are very high considering most expectations are upbeat.
Insmed Incorporated (INSM: NASDAQ)Insmed Incorporated (INSM), a biopharmaceutical company, is showing positive developments in its product portfolio. The company reiterated its 2023 guidance, expecting revenue between $295-305 million, with strategic plans to expand the use of its ARIKAYCE product.
Encouraging Phase 2 data for its TPIP drug, used in pulmonary hypertension treatment, highlights its commitment to developing effective therapies. Investors are eagerly awaiting the Phase 3 ASPEN Trial results for Brensocatib in Q2 2024, which could significantly boost the company's growth.
Market sentiment is bullish on INSM, particularly if the stock stays above the $22.50-$23.00 range, with an upside target set between $32.00 and $33.00.
$INSM Setting UpNASDAQ:INSM earning coming up Thursday but one to keep an eye on.
Nice volume pattern ahead of that event.
Long | INSMNASDAQ:INSM
Possible Scenario: LONG
Evidence: Price Action, Money Flow
Period: Less than two months.
TP1: 28.5$
TP2: 29.5$
TP3: 31$
*This is my idea and could be wrong 100%.
INSM ShortI see a repeating divergence in INSM for a decent short play after this market maker finishes with a target of 7.50
Big Potential For INSMED Daily
Hey guys, INSMED is in a bullish push with high volume buy executed and a water-carrying candle shape followed by short legs. The TIMEFRAME M1 shows us a kind of hammer candle with a high negotiated sales volume, it wanted to bounce back from the bollinger base. But it was a failure passing on its low point to come back to test the base and the top of the equilibrium zone. High probability of breaking the price with momentum then then the zone to interfere with the other and land on the high which follows.
With the filling of a gap of the bearish break before going to the lower unit we see an adjustment (for the TIMEFRAME H4). And on (the TIMEFRAME H1) the same then an excess before breakout of a zone of balance. Not enough buying force to test half of ANDREWS PITCHFORK's intermediate median.
Please LIKE & FOLLOW, thank you!
$INSM #Breakout SetupBiotech play that's been consolidating in a tight manner for 3 weeks. Looks ready to breakout.
INSM Bull Flag Approaching MacroINSM putting in a nice bull flag after earnings run up on strong volume. Entry through $35 with SL just below all the consolidation.
INSM Downtrend BreakoutBroke out from its downtrend once it hit its support and is now above it EMA it should now go up and test the resistance level.
Momentum Surge - INSM1. Not up three days in a row
2. Linear move up prior to consolidation
3. Young Trend
4. No breakouts or breakdowns during consolidation phase
5. Clean and low volatility consolidation
***see roboticinvesting.com for more details on Momentum Surge
INSM - Missed short & Long? Did we miss the short since it kept topping out??
We did have a target on the short to close the gap.
The long may not have been so obvious, with an exit at the 2nd arrow and red horizontal....
